一项评估高强度聚焦超声(HIFU)作为局部晚期胰腺癌患者第四种治疗模式作用的Meta分析
该Meta分析纳入19篇文章共939例患者,评估HIFU对晚期胰腺癌的疗效。结果显示HIFU组中位总生存期及治疗后6、12个月总生存期均高于对照组(p<0.05),HIFU联合化疗较传统治疗组疼痛减轻(p<0.05),CA19-9降低(p<0.05),并发症发生率低。作者认为HIFU是可行且安全的治疗模式,但缺乏足够随机临床试验,需新随机试验进一步评估。
要点
- HIFU组中位总生存期及6、12个月总生存期均高于对照组(p<0.05)。
- HIFU联合化疗较传统治疗组疼痛水平降低(p<0.05),CA19-9降低(p<0.05)。
- HIFU并发症发生率低,作者认为其为可行且安全的治疗模式。
核心结论
- HIFU似乎是晚期胰腺癌患者可行且安全的治疗模式,在生存和生活质量方面提供更优结局;鉴于缺乏足够随机临床试验,该Meta分析代表当前最佳证据,需新随机试验进一步评估。
研究设计与样本
- Meta分析,检索PubMed、Scopus和Cochrane数据库,遵循PRISMA指南;纳入19篇文章共939例患者;采用随机效应模型评估比值比、加权均数差和95%置信区间。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 缺乏显著数量的随机临床试验。
- 需要新的随机试验评估HIFU以进一步评价其结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: This study aimed to evaluate the outcomes of high-intensity focused ultrasound (HIFU) on patients with advanced pancreatic cancer.
METHODS: A literature search was performed in PubMed, Scopus and Cochrane databases, in accordance with the PRISMA guidelines. The Odds Ratio, Weighted Mean Difference, and 95% Confidence Interval were evaluated by means of the Random-Effects model.
RESULTS: Nineteen articles met the inclusion criteria, incorporating 939 patients. This study reveals that patients in the HIFU group presented increased median overall survival (OS), along with higher OS at 6 and 12 months after treatment compared with the control group (p < 0.05). Furthermore, patients treated with HIFU in conjunction with chemotherapy presented reduced levels of pain (p < 0.05) compared to the traditional treatment group. In addition, HIFU contributed to significant tumor responsiveness, in terms of CA19-9 reduction (p < 0.05). Finally, HIFU was a considerably safe treatment modality with a low incidence of complications.
CONCLUSION: These outcomes suggest that HIFU is a feasible and safe treatment modality for patients with advanced pancreatic cancer and provides enhanced outcomes regarding survival and quality of life. Given the lack of a significant number of randomized clinical trials, this meta-analysis represents the best currently available evidence. New randomized trials assessing HIFU are necessary to further evaluate their outcomes.
引用
- Fergadi, Magouliotis, Rountas, et al. A meta-analysis evaluating the role of high-intensity focused ultrasound (HIFU) as a fourth treatment modality for patients with locally advanced pancreatic cancer. Abdom Radiol (NY). 2021. PMID: 34718835. doi:10.1007/s00261-021-03334-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。